Eli Lilly and Company
LLY
$1,189.41
-$44.25-3.59%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 26.71B | 25.28B | 20.64B | 18.41B | 13.80B |
| Total Depreciation and Amortization | 2.10B | 2.04B | 2.00B | 1.90B | 1.89B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.07B | -446.50M | 2.27B | 2.40B | 3.11B |
| Change in Net Operating Assets | -4.80B | -6.39B | -8.09B | -6.64B | -7.86B |
| Cash from Operations | 28.08B | 20.48B | 16.81B | 16.06B | 10.94B |
| Capital Expenditure | -9.89B | -8.66B | -7.84B | -6.79B | -6.05B |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -10.47B | -1.72B | -661.00M | -549.70M | -300.00K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -4.74B | -1.16B | -2.47B | -2.75B | -5.06B |
| Cash from Investing | -25.10B | -11.53B | -10.97B | -10.09B | -11.11B |
| Total Debt Issued | 20.93B | 8.48B | 13.17B | 13.17B | 11.43B |
| Total Debt Repaid | -5.72B | -4.02B | -5.12B | -2.07B | -1.07B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -6.17B | -5.26B | -4.11B | -4.65B | -4.39B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -5.78B | -5.59B | -5.38B | -5.21B | -5.03B |
| Other Financing Activities | -650.30M | -677.30M | -772.30M | -793.10M | -810.20M |
| Cash from Financing | 2.61B | -7.06B | -2.21B | 440.50M | 120.80M |
| Foreign Exchange rate Adjustments | -20.40M | 306.60M | 371.60M | 9.90M | 205.10M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.57B | 2.19B | 4.00B | 6.42B | 152.00M |